BRVEBraveheart Bio Inc. Common Stock
27.58USD-4.80%Mkt Cap: 1.95B $P/E: —3d ago
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-18…
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
| Headline | Source | Time |
|---|---|---|
Older | ||
 Braveheart Bio (BRVE) Raised $382.5 Million In Its IPO Braveheart Bio (NasdaqGM: BRVE) completed its IPO and listed on the Nasdaq Global Market, with trading commencing before 11 August 2026. The company was added to the NASDAQ Composite Index shortly after the IPO, bringing the stock into a broad market benchmark. Following the listing and index inclusion, Braveheart Bio filed a large shelf registration to provide flexibility for future capital raises. This kind of rapid move from IPO to index inclusion has drawn attention to founder-led... | ||